BJDX net incomeQ2 2026-$2.32M
BJDX net income was -$2.32M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$1.96M a year earlier. For the full fiscal 2025 it was -$6.85M, compared with -$7.72M in fiscal 2024.
Bluejay Diagnostics Inc. (BJDX) financials
For the twelve months ended Jun 30, 2026, Bluejay Diagnostics Inc. reported -$7.27M of net income.
- Net income, TTM
- -$7.27M
- Cash
- $9.60M
- Market cap
- $2.6M
FY2020FY2025
FY2021FY2025
BJDX revenue and earnings growth
BJDX EPSQ2 2026-$1.12
BJDX diluted EPS was -$1.12 in fiscal Q2 2026 (ended Jun 30, 2026). For the full fiscal 2025 it was -$15.25.
BJDX free cash flowQ2 2026-$1.64M
BJDX free cash flow was -$1.64M in fiscal Q2 2026 (ended Jun 30, 2026). For the full fiscal 2025 it was -$6.23M, compared with -$8.13M in fiscal 2024.
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | $249.0K | - | - |
| Cost of revenue | - | - | - | $200.1K | - | - |
| Gross profit | - | - | - | $48.9K | - | - |
| Research and development | $3.05M | $3.47M | $5.71M | $4.15M | $1.15M | $527.3K |
| Selling, general and admin | $3.91M | $3.69M | $4.31M | $451.4K | $1.79M | $596.1K |
| Operating income | -$6.95M | -$7.17M | -$10.31M | -$9.32M | -$3.23M | -$1.20M |
| Interest expense | $839 | $823.0K | - | - | $6.4K | - |
| Net income | -$6.85M | -$7.72M | -$9.95M | -$9.30M | -$3.49M | -$1.16M |
| EPS, basic | -$15.25 | -$456.75 | -$14525.92 | -$295.04 | -$13.12 | -$11.84 |
| EPS, diluted | -$15.25 | -$456.75 | -$14525.92 | -$295.04 | -$13.12 | -$11.84 |
| Diluted shares | 449,043 | 45,848 | 685.25 | 31,506.125 | 266,325.688 | 98,350 |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
|---|---|---|---|---|---|---|
| Cash and equivalents | $5.16M | $4.30M | $2.21M | $10.11M | $19.05M | $912.4K |
| Inventory | - | - | - | - | - | $84.8K |
| Current assets | $5.46M | $4.90M | $3.22M | $11.79M | $20.66M | $1.06M |
| Total assets | $7.12M | $6.66M | $4.87M | $13.52M | $21.02M | $1.52M |
| Current liabilities | $1.12M | $810.4K | $1.77M | $1.64M | $637.2K | - |
| Total debt | - | - | - | - | $10.0K | - |
| Total liabilities | $1.14M | $927.9K | $1.97M | $1.98M | $637.2K | $1.85M |
| Shareholders' equity | $5.98M | $5.73M | $2.89M | $11.54M | $20.38M | -$4.21M |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$6.05M | -$7.82M | -$8.31M | -$7.74M | -$4.37M | -$508.7K |
| Capital expenditures | $173.7K | $306.8K | $704.2K | $1.20M | $23.9K | - |
| Free cash flow | -$6.23M | -$8.13M | -$9.02M | -$8.94M | -$4.39M | - |
| Investing cash flow | -$173.7K | -$306.8K | -$704.2K | -$1.20M | -$23.9K | - |
| Financing cash flow | $7.09M | $10.22M | $1.11M | $8.1K | $22.53M | $1.33M |
| Stock-based compensation | $6 | $20.1K | $189.2K | $433.0K | $68.5K | $3.7K |
| Depreciation and amortization | - | - | - | $156.6K | $145.7K | $157.0K |
Key ratios
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
|---|---|---|---|---|---|---|
| Gross margin | - | - | - | 19.6% | - | - |
| Operating margin | - | - | - | -3741.5% | - | - |
| Net margin | - | - | - | -3733.1% | - | - |
| Free cash flow margin | - | - | - | -3590.1% | - | - |
| Return on equity | -114.6% | -134.7% | -343.8% | -80.6% | -17.1% | - |
| Return on assets | -96.2% | -115.9% | -204.5% | -68.8% | -16.6% | -76.3% |
| Current ratio | 4.88 | 6.05 | 1.82 | 7.19 | 32.43 | - |
| Debt to equity | - | - | - | - | 0.00 | - |
Income statement
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Research and development | $1.44M | $811.8K | $586.1K | $785.6K | $889.9K | $784.8K | $554.0K | $551.7K | $1.03M | $1.33M | $1.29M | $1.40M |
| Selling, general and admin | $911.3K | $1.13M | $875.6K | $831.3K | $1.10M | $1.10M | $929.8K | $809.2K | $862.5K | $1.09M | $1.10M | $963.5K |
| Operating income | -$2.35M | -$1.94M | -$1.46M | -$1.62M | -$1.99M | -$1.89M | -$1.48M | -$1.36M | -$1.90M | -$2.43M | -$2.39M | -$2.34M |
| Interest expense | - | - | $187 | $200 | $222 | $230 | $729 | $190.6K | $626.5K | $5.2K | - | - |
| Net income | -$2.32M | -$1.92M | -$1.43M | -$1.60M | -$1.96M | -$1.86M | -$1.43M | -$1.48M | -$2.48M | -$2.33M | -$2.30M | -$2.30M |
| EPS, basic | -$1.12 | -$1.95 | - | -$4.04 | -$5.64 | -$13.46 | - | -$307.76 | -$1024.64 | -$1579.04 | - | -$66.68 |
| EPS, diluted | -$1.12 | -$1.95 | - | -$4.04 | -$5.64 | -$13.46 | - | -$307.76 | -$1024.64 | -$1579.04 | - | -$66.68 |
| Diluted shares | 2.1M | 984,668 | - | 393,633.75 | 346,780 | 138,503 | - | 47,779.25 | 2,415.75 | 1,474.5 | - | 34,467.75 |
Balance sheet
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $9.60M | $3.68M | $5.16M | $3.08M | $4.44M | $3.12M | $4.30M | $5.76M | $8.06M | $2.66M | $2.21M | $5.08M |
| Current assets | $9.81M | $3.97M | $5.46M | $3.35M | $4.75M | $3.57M | $4.90M | $6.57M | $9.02M | $3.45M | $3.22M | $6.53M |
| Total assets | $11.53M | $5.60M | $7.12M | $4.89M | $6.40M | $5.28M | $6.66M | $8.35M | $10.86M | $5.08M | $4.87M | $8.25M |
| Current liabilities | $2.12M | $1.41M | $1.12M | $1.15M | $1.04M | $1.32M | $810.4K | $1.05M | $2.06M | $1.53M | $1.77M | $2.80M |
| Total liabilities | $2.12M | $1.42M | $1.14M | $1.20M | $1.11M | $1.41M | $927.9K | $1.19M | $2.22M | $1.71M | $1.97M | $3.03M |
| Shareholders' equity | $9.41M | $4.18M | $5.98M | $3.69M | $5.29M | $3.87M | $5.73M | $7.16M | $8.64M | $3.37M | $2.89M | $5.21M |
Cash flow
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$1.50M | -$1.59M | -$1.45M | -$1.36M | -$2.05M | -$1.18M | -$1.45M | -$2.15M | -$1.91M | -$2.30M | -$2.78M | -$1.13M |
| Capital expenditures | $142.8K | $19.0K | - | - | - | - | $1.1K | $227 | $270.0K | $35.4K | $87.9K | $74.5K |
| Free cash flow | -$1.64M | -$1.61M | - | - | - | - | -$1.45M | -$2.15M | -$2.18M | -$2.34M | -$2.87M | -$1.20M |
| Investing cash flow | -$142.8K | -$15.3K | - | - | - | - | -$1.1K | -$227 | -$270.0K | -$35.4K | -$87.9K | -$74.5K |
| Financing cash flow | $7.56M | $124.1K | $3.71M | -$1.0K | $3.38M | -$985 | -$1.3K | -$147.9K | $7.58M | $2.79M | -$3.0K | $1.18M |
| Stock-based compensation | - | - | $74 | $183 | -$1.6K | $1.3K | -$2.6K | $4.8K | $6.0K | $11.9K | -$15.6K | -$42.5K |
Key ratios
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current ratio | 4.64 | 2.81 | 4.88 | 2.92 | 4.56 | 2.71 | 6.05 | 6.26 | 4.38 | 2.26 | 1.82 | 2.33 |
Source: XBRL data Bluejay Diagnostics Inc. files with the SEC, latest filing dated Aug 12, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures and share counts are restated for stock splits the filings show: 1-for-8, first reported Aug 14, 2024; 1-for-4, first reported Mar 6, 2026.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
BJDX peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| BJDX | - | - | -$7.27M | - | $2.6M |
| SYK | $26.30B | +7.9% | $3.62B | 13.8% | $124.05B |
| MMM | $25.25B | +1.7% | $3.54B | 14.0% | $95.67B |
| BSX | $21.07B | +8.9% | $3.50B | 16.6% | $61.96B |
| BDX | $23.25B | +17.4% | $941.00M | 4.0% | $57.71B |
| MDLN | $30.68B | - | $683.00M | 2.2% | $52.13B |
| RMD | $5.73B | +9.0% | $1.59B | 27.8% | $33.10B |
| DXCM | $5.10B | +13.0% | $991.00M | 19.4% | $29.62B |
| WST | $3.40B | +12.6% | $638.90M | 18.8% | $27.85B |
BJDX FAQ
4 questionsIs BJDX profitable?
No. Bluejay Diagnostics Inc. reported a net loss of $7.27M for the twelve months ended Jun 30, 2026.How much cash and debt does BJDX have?
Bluejay Diagnostics Inc. reported $9.60M in cash and cash equivalents on its most recent balance sheet in SEC filings.When did BJDX last report financial results?
The latest statements here come from Bluejay Diagnostics Inc.'s 10-Q filed on Aug 12, 2026, covering the period ended Jun 30, 2026.Where does this BJDX financial data come from?
Quantisnow builds these statements from the structured XBRL data Bluejay Diagnostics Inc. files with the SEC. It is provided for information only and is not investment advice.